Mundipharma Partners With Samsung Bioepis For Hong Kong And Taiwan

Partnership Covers Adalimumab, Etanercept, Trastuzumab and Bevacizumab

 
• By Akriti Seth
  
Handshake_Hong_Kong
Samsung Bioepis chooses Mundipharma to commercialize its first-wave biosimilar candidates in Taiwan and Hong Kong • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business